cybc1 Antibody

What is CYBC1 and what is its biological function?

CYBC1 (Cytochrome b-245 Chaperone 1) is a 187 amino acid protein with a molecular weight of approximately 20.8 kDa that functions as a chaperone necessary for stable expression of the CYBA and CYBB subunits of the cytochrome b-245 heterodimer. The protein is highly expressed in immune cells including macrophages, neutrophils, and monocytes, where it plays a critical role in the formation and stability of the NADPH oxidase complex . CYBC1 is localized in the endoplasmic reticulum (ER) and has been shown to regulate the abundance of gp91phox-p22phox heterodimer, which is essential for reactive oxygen species (ROS) production during the respiratory burst in phagocytes . Deficiency in CYBC1 results in reduced expression of gp91phox, the main subunit of NADPH oxidase, leading to impaired oxidative burst and compromised immune function .

What are the key applications for CYBC1 antibodies in research?

CYBC1 antibodies are valuable tools in various immunological research applications, with Western Blot being the most common application. Other important applications include:

• Western Blot: For detection and quantification of CYBC1 protein expression in cell lysates or tissue samples .

• Immunocytochemistry/Immunofluorescence: For visualization of CYBC1 subcellular localization in different cell types and investigation of co-localization with other proteins .

• ELISA: For quantitative measurement of CYBC1 in biological samples and patient specimens .

• Flow Cytometry: For analysis of CYBC1 expression in specific immune cell populations, particularly useful in evaluating NADPH oxidase components in neutrophils and monocytes from potential CGD patients .

• Immunoprecipitation: For studying protein-protein interactions involving CYBC1, particularly its association with NADPH oxidase components.

How do I select the appropriate CYBC1 antibody for my experimental needs?

When selecting a CYBC1 antibody for research, several factors should be considered:

• Antibody Type: Determine whether a polyclonal or monoclonal antibody is more suitable for your application. Polyclonal antibodies like those described in the search results can recognize multiple epitopes and may provide stronger signals, while monoclonal antibodies offer higher specificity for a single epitope .

• Species Reactivity: Ensure the antibody recognizes CYBC1 from your species of interest. CYBC1 orthologs have been identified in multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken .

• Application Compatibility: Verify that the antibody has been validated for your specific application (Western blot, immunofluorescence, ELISA, etc.) .

• Immunogen Information: Review the immunogen used to generate the antibody. For example, some CYBC1 antibodies are generated against recombinant human Cytochrome b-245 chaperone 1 protein (43-187AA) .

• Conjugation: Consider whether you need a conjugated antibody (e.g., biotin-conjugated) for specific detection methods or multiplexing capabilities .

How do mutations in CYBC1 affect NADPH oxidase function and what insights can CYBC1 antibodies provide?

Mutations in CYBC1 have been identified as a novel cause of Chronic Granulomatous Disease (CGD), specifically autosomal recessive CGD type 5 (AR-CGD5). These mutations lead to impaired NADPH oxidase function through several mechanisms that can be investigated using CYBC1 antibodies:

• Protein Expression Analysis: CYBC1 antibodies in Western blot analysis can confirm the absence or reduced expression of CYBC1 protein in patients with suspected mutations. For example, in one case study, a homozygous mutation (p.Tyr2Ter) resulted in undetectable levels of EROS protein compared to healthy controls .

• Effect on NADPH Oxidase Components: CYBC1-deficient cells show significantly reduced expression of gp91phox and p22phox, which can be quantified using appropriate antibodies. In CYBC1 knockout cell lines, Western blot analysis revealed the absence of detectable gp91phox and much lower p22phox expression compared to control cells .

• Cell Type-Specific Effects: Interestingly, CYBC1 deficiency appears to have differential effects on neutrophils versus macrophages. In mouse studies, while macrophages from bc017643 (mouse ortholog of CYBC1) knockout mice had a similar ROS deficit as those from gp91phox/Cybb-deficient mice, neutrophils from bc017643-knockout mice retained some ROS generation capacity . CYBC1 antibodies can help investigate these cell-specific differences in human cells.

• Therapeutic Potential: Reintroduction of CYBC1/EROS using lentiviral vectors has been shown to restore gp91phox expression and oxidase activity in CYBC1-deficient cells, suggesting potential therapeutic approaches that can be monitored using CYBC1 antibodies .

What are the optimal methodologies for investigating CYBC1's role in different immune cell populations?

Investigating CYBC1's role across immune cell populations requires combining various techniques:

• Flow Cytometry with CYBC1 Antibodies: This approach allows quantification of CYBC1 expression in different immune cell subsets. In one study, CYBC1 deficiency led to abnormal gp91phox protein expression/function in neutrophils and monocytes (about 50%) and severely compromised B cell subset (gp91phox < 15%) .

• Functional Assays: Dihydrorhodamine (DHR) assay or Nitro Blue Tetrazolium (NBT) test can be used alongside CYBC1 antibody staining to correlate CYBC1 expression with respiratory burst capacity in different immune cells .

• Cell-Specific Knockout Models: Generation of cell-specific CYBC1 knockout models followed by immunophenotyping with CYBC1 antibodies helps elucidate cell-type specific functions. This is particularly relevant given the distinct phenotypes observed in neutrophils versus macrophages in CYBC1-deficient models .

• Single-Cell Analysis: Combining single-cell RNA sequencing with CYBC1 protein detection can provide insights into the heterogeneity of CYBC1 expression and function across immune cell subsets and states of activation.

• Tissue-Specific Expression: Immunohistochemistry with CYBC1 antibodies in different tissues can reveal potential tissue-specific roles of CYBC1 beyond hematopoietic cells.

How can CYBC1 antibodies help differentiate between different forms of Chronic Granulomatous Disease?

Chronic Granulomatous Disease (CGD) can be caused by mutations in several genes encoding NADPH oxidase components. CYBC1 antibodies can be valuable in differential diagnosis:

In AR-CGD5 specifically, CYBC1 antibodies reveal:

• Absence/significant reduction of CYBC1 protein expression

• Reduced expression of both gp91phox and p22phox

• Impaired respiratory burst similar to other CGD types

Some distinctive features of CYBC1-deficient CGD include:

• An excess of colitis compared to other CGD types

• A distinct profile of infections suggesting more pronounced macrophage dysfunction

• Unusual autoimmune manifestations like autoimmune hemolytic anemia

What technical challenges exist in detecting endogenous CYBC1 in different experimental systems?

Several technical challenges must be addressed when detecting endogenous CYBC1:

• Low Expression Levels: CYBC1 may be expressed at relatively low levels in certain cell types or tissues, requiring sensitive detection methods. Signal amplification techniques or highly optimized antibody concentrations may be necessary.

• Isoform Specificity: Up to two different isoforms have been reported for CYBC1 . Researchers must ensure their antibodies can detect the specific isoform of interest, or use antibodies targeting conserved regions if all isoforms are relevant.

• Cross-Reactivity Concerns: Given the high sequence similarity (89%) between human CYBC1 and its mouse ortholog , ensuring species specificity is critical when working with model systems.

• Subcellular Localization: As CYBC1 is primarily localized to the ER , subcellular fractionation protocols must be optimized to enrich for this compartment when preparing samples for Western blot or other analyses.

• Fixation Sensitivity: For immunocytochemistry or immunofluorescence applications, determining the optimal fixation method is crucial, as some epitopes may be sensitive to particular fixatives, potentially affecting antibody binding.

What is the recommended protocol for using CYBC1 antibodies in Western blot analysis?

When using CYBC1 antibodies for Western blot analysis, the following protocol is recommended based on successful detection in published research:

• Sample Preparation:

  • For cell lysates: Lyse cells in RIPA buffer containing protease inhibitors

  • For tissue samples: Homogenize in RIPA buffer with protease inhibitors

  • Typical protein concentration: 20-50 μg per lane is recommended

• Gel Electrophoresis:

  • Use 10-15% SDS-PAGE gels (CYBC1 is approximately 20.8 kDa)

  • Include positive controls such as lysates from cells known to express CYBC1 (e.g., neutrophils, monocytes, or macrophages)

  • Include negative controls such as CYBC1 knockout cell lines when available

• Transfer and Blocking:

  • Transfer to PVDF or nitrocellulose membrane

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour

• Primary Antibody Incubation:

  • Dilute CYBC1 antibody according to manufacturer's recommendations (typically 1:500-1:2000)

  • Incubate overnight at 4°C with gentle agitation

• Visualization:

  • For unconjugated primary antibodies: Use appropriate HRP-conjugated secondary antibody

  • For biotin-conjugated CYBC1 antibodies: Use streptavidin-HRP

  • Develop using ECL substrate and detect bands at approximately 20.8 kDa

• Troubleshooting Tips:

  • If no signal is detected, consider longer exposure times or increasing antibody concentration

  • High background may require more stringent washing or diluting antibody further

  • Multiple bands may indicate post-translational modifications or detection of isoforms

How can CYBC1 antibodies be utilized to assess NADPH oxidase function in patient samples?

CYBC1 antibodies can be integrated into a comprehensive assessment of NADPH oxidase function in patient samples using the following approaches:

• Multi-parameter Flow Cytometry:

  • Combine surface markers to identify cell populations (CD15+ neutrophils, CD14+ monocytes)

  • Use permeabilization to enable intracellular staining with CYBC1 antibodies

  • Co-stain with antibodies against other NADPH oxidase components (gp91phox, p22phox)

  • Correlate with DHR assay results for functional assessment of oxidative burst

• Western Blot Analysis of Patient Cells:

  • Isolate peripheral blood mononuclear cells or neutrophils from patient samples

  • Perform Western blot analysis using CYBC1 antibodies and antibodies against NADPH oxidase components

  • Compare expression levels between patients and healthy controls or heterozygous carriers

• Ex Vivo Functional Studies:

  • Isolate neutrophils or monocytes from patient samples

  • Stimulate with PMA or other activators of NADPH oxidase

  • Measure ROS production using luminol-enhanced chemiluminescence or other methods

  • Correlate ROS production with CYBC1 expression determined by antibody-based methods

• Genetic Confirmation:

  • In cases with suspected CYBC1 deficiency based on protein expression analysis, confirm with genetic testing for mutations in the CYBC1 gene

  • Use heterozygous family members as controls when available

What controls should be included when using CYBC1 antibodies in research?

Appropriate controls are essential for reliable results when using CYBC1 antibodies:

• Positive Controls:

  • Cell lines or primary cells known to express CYBC1 (e.g., THP-1 cells, neutrophils, monocytes)

  • Recombinant CYBC1 protein for Western blot standard curve

  • Samples from healthy individuals when working with patient specimens

• Negative Controls:

  • CYBC1 knockout cell lines (CRISPR-generated)

  • Cells types with minimal CYBC1 expression

  • Primary antibody omission control

  • Isotype control for flow cytometry

• Specificity Controls:

  • Pre-adsorption of antibody with immunizing peptide/protein

  • Demonstration of reduced signal in knockdown/knockout samples

  • Detection of expected molecular weight band (20.8 kDa)

• Heterozygote Controls:

  • When studying CYBC1 mutations, include samples from heterozygous individuals who show intermediate levels of CYBC1 expression

• Functional Correlates:

  • Include assays that correlate CYBC1 expression with functional outcomes (e.g., DHR assay, NBT test)

  • Demonstrate rescue of phenotype with reconstitution of CYBC1 expression

How can CYBC1 antibodies contribute to developing therapeutic strategies for CGD patients with CYBC1 mutations?

CYBC1 antibodies can play vital roles in developing and monitoring therapeutic approaches for CYBC1-deficient CGD:

• Gene Therapy Development:

  • CYBC1 antibodies can be used to confirm successful transduction and expression of functional CYBC1 protein in patient cells after gene therapy

  • Western blot analysis with CYBC1 antibodies can verify proper protein expression levels

  • Restoration of gp91phox and p22phox expression can be monitored as downstream effects of successful CYBC1 reconstitution

• Small Molecule Screening:

  • High-throughput screening for compounds that may stabilize mutant CYBC1 or enhance residual activity

  • CYBC1 antibodies can be used in assays to measure protein stabilization or increased expression

  • Correlation with functional assays to confirm improved NADPH oxidase activity

• Ex Vivo Cell Therapy:

  • CYBC1 antibodies can help monitor correction of patient-derived hematopoietic stem cells

  • Flow cytometry with CYBC1 antibodies can be used to sort successfully modified cells

• Biomarker Development:

  • CYBC1 antibodies may help identify biomarkers of disease severity or treatment response

  • Correlation of CYBC1 expression levels with clinical parameters and outcome measures

• Chaperone Therapy Approaches:

  • Given CYBC1's role as a chaperone for NADPH oxidase components, CYBC1 antibodies can help evaluate the effectiveness of alternative chaperone proteins or chaperone-inducing compounds

What are the key considerations for developing new CYBC1 antibodies for specialized research applications?

Developing new CYBC1 antibodies for specialized applications requires careful consideration of several factors:

• Epitope Selection:

  • Choose epitopes in conserved regions for cross-species applications

  • Target functional domains for antibodies intended to block protein-protein interactions

  • Avoid regions with post-translational modifications if studying native protein

  • Consider hydrophilicity and surface accessibility for applications with native protein

• Validation Requirements:

  • Validate specificity using CYBC1 knockout controls

  • Demonstrate application-specific performance (Western blot, IHC, flow cytometry)

  • Confirm detection of endogenous protein at expected molecular weight

  • Test in relevant cell types (neutrophils, monocytes, macrophages)

• Specialized Applications:

  • For proximity ligation assays: Develop antibodies from different species targeting different CYBC1 epitopes

  • For super-resolution microscopy: Consider fluorophore conjugation stability and brightness

  • For ChIP applications: Ensure ability to recognize cross-linked protein

• Purification and Storage:

  • Optimize purification methods (e.g., affinity purification against the immunogen)

  • Determine appropriate storage conditions (e.g., 50% glycerol, -20°C or -80°C)

  • Test freeze-thaw stability

• Reproducibility Considerations:

  • For monoclonal antibodies: ensure stable hybridoma lines

  • For polyclonal antibodies: consider immunization strategies that yield consistent responses

  • Document lot-to-lot variation and provide validation data for each lot

What emerging technologies might enhance CYBC1 antibody-based research?

Several cutting-edge technologies could significantly advance CYBC1 antibody applications:

• Single-Cell Proteomics:

  • Integration of CYBC1 antibodies into single-cell proteomics platforms could reveal cell-to-cell variation in CYBC1 expression and its correlation with NADPH oxidase components

  • This approach would be particularly valuable for understanding the heterogeneity in immune cell responses in CGD patients

• Intrabodies and Nanobodies:

  • Development of CYBC1-specific intrabodies (intracellular antibodies) or nanobodies (single-domain antibodies) could enable live-cell imaging of CYBC1 dynamics

  • These tools could help visualize CYBC1's interactions with NADPH oxidase components in real-time

• Antibody-Based Proximity Labeling:

  • CYBC1 antibodies conjugated to enzymes like APEX2 or BioID could identify novel CYBC1 interaction partners through proximity-dependent labeling

  • This approach could uncover previously unknown functions of CYBC1 beyond its role in NADPH oxidase assembly

• Spatially Resolved Transcriptomics and Proteomics:

  • Combining CYBC1 antibody staining with spatial transcriptomics could reveal tissue-specific expression patterns and regulatory mechanisms

  • This would be particularly valuable for understanding CYBC1's role in tissue-specific manifestations of CGD

• CRISPR Screens with Antibody-Based Readouts:

  • High-throughput CRISPR screens using CYBC1 antibody staining as a readout could identify genes that regulate CYBC1 expression or function

  • This approach could uncover new therapeutic targets for enhancing CYBC1 activity